全球抗結核治療藥市場:各類藥物,各終端用戶,各地區 - 成長,趨勢,預測
市場調查報告書
商品編碼
613119

全球抗結核治療藥市場:各類藥物,各終端用戶,各地區 - 成長,趨勢,預測

Anti-tuberculosis Therapeutics Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球抗結核治療藥市場預計2018~2023年的年複合成長率為6.0%。由於結核的認識度高漲,北美獨佔該市場。

本報告提供全球抗結核治療藥市場相關調查,市場概要與成長趨勢,競爭趨勢,各地區趨勢,及加入此市場的主要企業的簡介等彙整資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要影響因素

第5章 市場概要

  • 目前市場方案
  • 波特五力分析

第6章 促進要素,阻礙要素,機會,課題分析

  • 促進要素
  • 阻礙要素
  • 市場機會
  • 課題

第6章 市場區隔

  • 各類藥物
  • 各終端用戶
    • 醫院、診所
    • 政府機關
    • 非營利團體
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭環境

  • 合併、收購
  • 協定,聯合,聯盟
  • 新產品上市

第9章 主要企業

  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi
  • 其他

第10章 市場未來

簡介目錄
Product Code: 55411

Factors, such as rising prevalence of tuberculosis, growing initiative from government organization for tuberculosis awareness, collaboration between academic and private players for novel drug development, and rising incidence of MDR and XDR cases in developing countries, are propelling the growth of the market studied.

According to the WHO's 2020 Global Tuberculosis (TB) Report, a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent. Overall, the global burden of TB and MDR-TB is a challenge for leading medical regulatory institutions. The active interest of both medical communities and government alike, in curbing TB, is expected to increase the number of diagnoses for TB. This is, in turn, driving the growth of the global anti-tuberculosis therapeutics market, supported by the increasing global prevalence of TB and MDR-TB.

Key Market Trends

Hospitals/Clinics are Expected to Witness the Fastest Growth in the Coming Future

The WHO's strategy to prevent TB includes engaging all relevant healthcare providers in tuberculosis (TB) care, while control through public-private mix approach remains an essential component of the strategy. The TB prevalence rate is more in countries, like China, India, and Africa, hence, the governments of these respective countries are trying to decrease the rate by increasing government initiatives and the number of hospitals.

As per 2019 Global Tuberculosis Report by the WHO, developing countries accounted for most of the global total TB cases, including India (27%), China (9%), Indonesia (8%), and the Philippines (6%). The developing countries mostly rely on the hospitals for healthcare access. Hence high incidence in the regions will boost the market in hospitals and clinics.

Asia-Pacific is Expected to be the Largest Market Over the Forecast Period

As per 2019 Global Tuberculosis Report by the WHO, geographically, most TB cases in 2018 were in the WHO regions of South-East Asia (44%), Africa (24%) and the Western Pacific (18%). As a result, a large number of cases are found in the Asia-Pacific region, which is expected to help the region dominate the market. Moreover, most of the global pharmaceutical companies have penetrated in developing countries like India and China, which is also expected to increase the availability of therapeutics and boost the market growth.

Competitive Landscape

The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in the R&D, imore small to mid-sized companies are estimated to enter into the market in the coming future.

Currently, companies such as Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson hold the largest market share.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Tuberculosis
    • 4.2.2 Growing Initiative from Government Organization for Tuberculosis Awareness
    • 4.2.3 Rising Incidence of MDR and XDR Cases in Developing Countries
  • 4.3 Market Restraints
    • 4.3.1 Adverse Side Effects of Anti-tuberculosis Drugs
    • 4.3.2 High Cost of MDR and XDR TB Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Isoniazid
    • 5.1.2 Rifampin
    • 5.1.3 Ethambutol
    • 5.1.4 Pyrazinamide
    • 5.1.5 Fluoroquinolones
    • 5.1.6 Bedaquiline
    • 5.1.7 Amynoglycosides
    • 5.1.8 Thioamides
    • 5.1.9 Cyclic Peptides
    • 5.1.10 Other Drug Classes
  • 5.2 By End User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Government Agencies
    • 5.2.3 Non Profit Organizations
    • 5.2.4 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Lupin Limited
    • 6.1.2 Macleods Pharmaceuticals Ltd
    • 6.1.3 Otsuka Pharmaceutical Co. Ltd
    • 6.1.4 Johnson and Johnson
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS